JITTERBIT
9.11.2021 09:02:10 CET | Business Wire | Press release
Jitterbit, the API transformation company, has revealed its first ever Integration Trends Report. It gives an unparalleled view of how companies responded to the seismic challenges of the global pandemic - and how they are building back stronger.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005727/en/
Analysing anonymised data of over 2,000 customers across EMEA from 2020 - 2021, the report reveals macro trends across markets as companies innovated to meet rapidly changing customer needs, move more of their services online and enable remote working for employees.
“The trends emerging all point to a need to move quickly and provide the highest level of product, service and employee experience in order to compete and survive, with companies turning to no-code/ low-code and microservices in readiness for the next stage of hypergrowth. ” said Steve Sichtman, VP Multi Channel Development, Jitterbit
Rather than freeze or reduce spend on integrating new technologies, companies actively sought to spend more on integration across a number of key areas:
Service Experience and eCommerce Spend
- With many physical locations closed or severely disrupted in 2020 and unprecedented customer demand for online service, companies responded by increasing their eCommerce integration investment by 99% during the year.
- Companies increased spend on Services Experience 360 on average by 50% in 2020. Growth in the services front-end with applications such as BMC Helix ITSM, Jira, Zendesk and others was also matched with growth in the services back-end around IT operations.
Product Experience
- Companies increased their spend on Product 360 (optimizing the product life cycle) in 2020 by 26%.
- Data from 2020 reveals a double digit increase in demand around large ERP systems from vendors like SAP and Microsoft. Optimizing business processes was a key focus as businesses realized the essential value of having automated processes across the entire manufacturing, supply chain and sales processes.
Employee Experience
- Companies increased their spend on Employee Experience 360 in 2020 by 72%. Increased reliance on a remote workforce, new communications tools, and fluctuating budgets all contributed to this increased focus on employee experience.
Low-code, microservice and marketplace popularity
- Low-code and no-code gained popularity because of the many hyper automation benefits it offers to IT teams, becoming in the process a key differentiator when selecting an integration platform-as-a-service (iPaaS).
- Many companies have already moved to microservices, rather than API, architecture. Self-contained and ready to go, microservices can be plugged into a wide array of applications and leveraged throughout an organization. Now, there’s evidence of increased demand for iPaaS systems that work closely with microservices. This empowers business users to plug different microservices together to create specialized applications without no-code.
- Many Enterprise and Software companies are finding it’s no longer sufficient to offer an API for the outside world to connect to them. They must overcome the “integration burden” to improve retention and stickiness. The answer lies in integration marketplaces where companies can offer pre-built and certified API integrations and solutions to their partners and customers.
This Integration Trends report demonstrates how trends in integration technology - the way modern businesses automate the connections between the myriad softwares, platforms and technologies they deploy - reflect how businesses respond to meet the macro challenges and opportunities they face.
The report also provides actionable insights on what businesses now need to focus on as countries across EMEA move into the post-pandemic period.
To download the full report, visit: https://info.jitterbit.com/jitterbit-trends-report.html
Ends.
About Jitterbit, Inc.
Jitterbit, the API transformation company, makes it quicker and easier for businesses to exploit data from any source, empowering them to rapidly innovate and make faster, more effective decisions. The Jitterbit Harmony API integration platform and API360 solutions enable companies to quickly connect SaaS, on-premises, and cloud applications and instantly infuse intelligence into any business process. To learn more, visit www.jitterbit.com or follow us on LinkedIn and on Twitter at @Jitterbit .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005727/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom